In Silico Discovery of Novel Topoisomerase IIα Inhibitors with Enhanced Antiproliferative Activity in Breast Cancer

Abstract Human topoisomerase IIα (TOP2A) is frequently overexpressed in aggressive cancers, making it an attractive therapeutic target. Herein, we employed an integrated in silico and experimental approach to identify novel TOP2A inhibitors. A library of 669,069 filtered, drug-like bioactive small molecules from PubChem was screened against human TOP2A (PDB ID: 5GWK) using Schrödinger Maestro with Glide SP and XP docking, yielding 202 compounds with docking scores superior to etoposide. Subsequent filtering for PAINS, ADMET, and selectivity assessment against other human type I and type II topoisomerases yielded 21 ligands. Docking against multidomain TOP2A (PDB ID: 6ZY8) revealed preferential binding at the DNA-gate over the ATP-binding N-gate region, with L8 (pitavastatin) achieving the highest docking score. Based on their docking score, selectivity, and commercial availability, five ligands were selected for experimental evaluation. A cell viability assay showed that pitavastatin and L21 (PubChem CID: 7369491) exhibited potent cytotoxicity against MDA-MB-231 and MCF-7 breast cancer cells, respectively, with reduced toxicity against normal HEK293 cells. Both ligands induced S-phase arrest and late apoptosis in MDA-MB-231 cells, with pitavastatin outperforming etoposide. The in vitro plasmid relaxation assay confirmed that all five ligands inhibited TOP2A activity consistent with the poison mechanism, while pitavastatin exhibited a nonintercalative mode of binding to DNA. Molecular dynamics simulations for pitavastatin supported stable binding within the TOP2A active site. These findings identify pitavastatin as a promising repurposed candidate for TOP2A-targeted therapy, particularly against the triple-negative breast cancer cell line MDA-MB-231.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-17
DOI
https://doi.org/10.1021/acsomega.6c06715
Primary Topic
Cancer therapeutics and mechanisms
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

In Silico Discovery of Novel Topoisomerase IIα Inhibitors with Enhanced Antiproliferative Activity in Breast Cancer

Yogendra Nayak, Venkata Narayanan Naranammalpuram Sundaram, Deepak Samuel, Satabdi DebRoy et al.
ACS Omega
Cancer therapeutics and mechanisms
article

In Silico Discovery of Novel Topoisomerase IIα Inhibitors with Enhanced Antiproliferative Activity in Breast Cancer

Yogendra Nayak, Venkata Narayanan Naranammalpuram Sundaram, Deepak Samuel, Satabdi DebRoy, Duraippandi Palanimuthu, Krishnaprasad Baby, Anwesha Saikia, Basavarajeshwari Police Patil, Anju Sebastian
article en

Abstract

Abstract Human topoisomerase IIα (TOP2A) is frequently overexpressed in aggressive cancers, making it an attractive therapeutic target. Herein, we employed an integrated in silico and experimental approach to identify novel TOP2A inhibitors. A library of 669,069 filtered, drug-like bioactive small molecules from PubChem was screened against human TOP2A (PDB ID: 5GWK) using Schrödinger Maestro with Glide SP and XP docking, yielding 202 compounds with docking scores superior to etoposide. Subsequent filtering for PAINS, ADMET, and selectivity assessment against other human type I and type II topoisomerases yielded 21 ligands. Docking against multidomain TOP2A (PDB ID: 6ZY8) revealed preferential binding at the DNA-gate over the ATP-binding N-gate region, with L8 (pitavastatin) achieving the highest docking score. Based on their docking score, selectivity, and commercial availability, five ligands were selected for experimental evaluation. A cell viability assay showed that pitavastatin and L21 (PubChem CID: 7369491) exhibited potent cytotoxicity against MDA-MB-231 and MCF-7 breast cancer cells, respectively, with reduced toxicity against normal HEK293 cells. Both ligands induced S-phase arrest and late apoptosis in MDA-MB-231 cells, with pitavastatin outperforming etoposide. The in vitro plasmid relaxation assay confirmed that all five ligands inhibited TOP2A activity consistent with the poison mechanism, while pitavastatin exhibited a nonintercalative mode of binding to DNA. Molecular dynamics simulations for pitavastatin supported stable binding within the TOP2A active site. These findings identify pitavastatin as a promising repurposed candidate for TOP2A-targeted therapy, particularly against the triple-negative breast cancer cell line MDA-MB-231.

ACS Omega
Central University of Karnataka (IN), Manipal Academy of Higher Education (IN)
University Grants Commission, Science and Engineering Research Board
Good health and well-being
Cancer therapeutics and mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon